2025
Impact of RSVpreF vaccination on reducing the burden of respiratory syncytial virus in infants and older adults
Du Z, Pandey A, Moghadas S, Bai Y, Wang L, Matrajt L, Singer B, Galvani A. Impact of RSVpreF vaccination on reducing the burden of respiratory syncytial virus in infants and older adults. Nature Medicine 2025, 31: 647-652. PMID: 39789324, PMCID: PMC11835734, DOI: 10.1038/s41591-024-03431-7.Peer-Reviewed Original ResearchConceptsRespiratory syncytial virusSyncytial virusRSV diseaseImpact of vaccinationBurden of respiratory syncytial virusVaccination of pregnant womenRSV-related mortalityProtein-based vaccinesVaccination of older adultsRSV vaccinePregnant womenSeasonal influenzaVaccine uptake ratesInfant hospitalizationClinical trialsPrefusion FHospital costsInfantsHealth burdenAdult immunizationVaccineOlder adultsHospitalEnhanced uptakeHigh-income countries
2023
Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study
Shoukat A, Abdollahi E, Galvani A, Halperin S, Langley J, Moghadas S. Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study. The Lancet Regional Health - Americas 2023, 28: 100629. PMID: 38026446, PMCID: PMC10663690, DOI: 10.1016/j.lana.2023.100629.Peer-Reviewed Original ResearchEntire birth cohortPregnant womenBirth cohortCost-effectiveness analysisRSV seasonHigh riskBudget impactRespiratory syncytial virus diseaseSocietal perspectiveAnnual budget impactFirst RSV seasonHealth benefitsRespiratory syncytial virusImmunisation of infantsYears of ageLow budget impactMonths of ageNet monetary benefitMaternal vaccinesRSV infectionPassive immunisationGestational ageImmunisation strategiesSyncytial virusVaccine strategies
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply